| Literature DB >> 21110891 |
Hsien-Chung Tseng1, Catey L Harwell, Collin H Martin, Kristala L J Prather.
Abstract
BACKGROUND: The ability to synthesize chiral building block molecules with high optical purity is of considerable importance to the fine chemical and pharmaceutical industries. Production of one such compound, 3-hydroxyvalerate (3HV), has previously been studied with respect to the in vivo or in vitro enzymatic depolymerization of biologically-derived co-polymers of poly(3-hydroxybutyrate-co-3-hydroxyvalerate). However, production of this biopolymeric precursor typically necessitates the supplementation of a secondary carbon source (e.g., propionate) into the culture medium. In addition, previous approaches for producing 3HV have not focused on its enantiopure synthesis, and thus suffer from increased costs for product purification.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21110891 PMCID: PMC3000843 DOI: 10.1186/1475-2859-9-96
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Figure 1Schematic representation of chiral 3HV production via the threonine biosynthesis pathway in metabolically engineered . Genes in bold are overexpressed while disrupted pathway steps are indicted by the "no" symbols. The carbon sources and main metabolic products in the system are enclosed by rectangular boxes with thick and thin lines, respectively. For glycerol utilization [43,44], a glycerol kinase (GK) phosphorylates glycerol to glycerol-3-phosphate, followed by oxidation to dihydroxyacetone phosphate that enters glycolysis. The oxidation reaction is catalyzed by a membrane enzyme called glycerol-3-phosphate dehydrogenase (GlpD) with concomitant production of ubiquinol (UQH2) from ubiquinone (UQ). Electrons stored in the ubiquinol are then transferred through the aerobic respiratory chain coupled with proton translocation from cytoplasm to periplasm. Both ATP and NADPH can be synthesized by an H+-driven proton movement from periplasm to cytoplasm, catalyzed by an ATP synthase and a membrane-bound transhydrogenase (PntAB), respectively.
Figure 23HV biosynthesis from glucose and propionate. This figure shows shake-flask production of chiral 3HV by recombinant E. coli strain HCT 10 grown in LB supplemented with 20 g/L glucose and 20 mM sodium propionate. Over-expressed genes are indicated in the table below the graph.
Figure 33HV biosynthesis from glucose and 2-ketobutyrate. This figure shows shake-flask production of chiral 3HV by recombinant E. coli grown in LB supplemented with 20 g/L glucose and 3 g/L sodium 2-ketobutyrate. Effects of overexpressing ptb-buk and using acetate pathway knockout strain HCT 20 (with additional deletions of ackA-pta. poxB, and atoDA genes compared to HCT 10) on 3HV production are compared. All strains contained the same set of plasmids pET-PB-B, and pCDF-T-H (for (S)-3HV synthesis) or pCDF-T-P (for (R)-3HV synthesis).
Figure 43HV biosynthesis from glucose and threonine. This figure shows shake-flask production of chiral 3HV by recombinant E. coli strain HCT 10 grown in LB supplemented with 20 g/L glucose and 3 g/L threonine. Chiral 3HV production using alternative threonine deaminases (encoded by ilvA) from E. coli and C. glutamicum is compared. All strains contained the same set of plasmids pET-PB-B, pCOLA-Icg or pCOLA-Iec as indicated, and pCDF-T-H (for (S)-3HV synthesis) or pCDF-T-P (for (R)-3HV synthesis).
Figure 53HV biosynthesis solely from glucose. This figure shows shake-flask production of chiral 3HV in various knock-out strains as described in Table 1. Cells were grown in LB supplemented with 20 g/L glucose. The top and bottom dashed lines represent the acetate titers produced from E. coli strain HCT 10 and HCT 20 harboring empty plasmids, respectively. All strains contained the same set of plasmids pET-PB-B, pCOLA-Tecm-Icg, and pCDF-T-H (for (S)-3HV synthesis) or pCDF-T-P (for (R)-3HV synthesis). The recombinant HCT 10 strains carrying an empty pCOLAduet-1 in place of pCOLA-Tecm-Icg, as control strains, produced essentially no 3HV (data not shown).
Figure 63HV biosynthesis solely from glycerol. This figure shows shake-flask production of chiral 3HV in various knock-out strains as described in Table 1. Cells were grown in LB supplemented with 20 g/L glycerol. The amounts of (S)-3HB produced in both recombinant HCT 10 and HCT 21 strains were too low to be quantified due to a low detection limit by DAD at 210 nm; therefore, the 3HV/3HB ratios were not applicable (NA) to the (S)-isomer. All strains contained the same set of plasmids pET-PB-B, pCOLA-Tecm-Icg, and pCDF-T-H (for (S)-3HV synthesis) or pCDF-T-P (for (R)-3HV synthesis).
Figure 7Determination of the stereochemistry of 3HV. HPLC spectra of (A) racemic 3HV standards after boiling in methanol, (B) culture medium from the recombinant strain HCT 10 expressing bktB, phaB, tesB, and ptb-buk after boiling in methanol, and (C) culture medium from the recombinant strain HCT 10 expressing bktB, hbd, tesB, and ptb-buk after boiling in methanol are shown.
E. coli strains, plasmids and oligonucleotides used
| Name | Relevant Genotype | Reference |
|---|---|---|
| DH10B | F- | Invitrogen |
| ElectroTen-Blue | Δ( | Stratagene |
| MG1655 | F- λ- | ATCC 700926 |
| HCT 10 | MG1655 Δ | This study |
| HCT 11 | MG1655 Δ | This study |
| HCT 20 | MG1655 Δ | This study |
| HCT 21 | MG1655 Δ | This study |
| pETDuet-1 | ColE1(pBR322) | Novagen |
| pCDFDuet-1 | CloDF13 | Novagen |
| pCOLADuet-1 | COLA | Novagen |
| pET-B | pETDuet-1 harboring | This study |
| pET-PB-B a | pETDuet-1 harboring | This study |
| pCDF-H | pCDFDuet-1 harboring | This study |
| pCDF-T-H a | pCDFDuet-1 harboring | This study |
| pCDF-P | pCDFDuet-1 harboring | This study |
| pCDF-T-P a | pCDFDuet-1 harboring | This study |
| pCOLA-Iec | pCOLADuet-1 harboring | This study |
| pCOLA-Icg | pCOLADuet-1 harboring | This study |
| pCOLA-Tec-Icg a | pCOLADuet-1 harboring | This study |
| pCOLA-Tecm-Icg a | pCOLADuet-1 harboring | This study |
| bktB_US_EcoRI | Sigma-Genosys | |
| bktB_DS_XhoI | Sigma-Genosys | |
| hbd_US_NdeI | ATT | Sigma-Genosys |
| hbd_DS_AvrII | ATT | Sigma-Genosys |
| phaB_US_MfeI | ATT | Sigma-Genosys |
| phaB_DS_AvrII | ATT | Sigma-Genosys |
| tesB_US_NcoI | ATT | Sigma-Genosys |
| tesB_DS_NotI | ATT | Sigma-Genosys |
| ilvAec_US_NdeI | ATTA | Sigma-Genosys |
| ilvAec_DS_AvrII | ATTA | Sigma-Genosys |
| ilvAcg_US_NdeI | ATTA | Sigma-Genosys |
| ilvAcg_DS_AvrII | ATTA | Sigma-Genosys |
| thrABC_US_BamHI | ATTA | Sigma-Genosys |
| thrABC_US_NcoI | ATTA | Sigma-Genosys |
| thrABC_DS_SalI | ATTA | Sigma-Genosys |
a Each gene is under the control of the T7lac promoter with a ribosome binding site.
b Primers were synthesized at Sigma-Genosys, St. Louis, MO.
c Restriction enzyme sites used in the cloning are shown in underlined italics.